In the ninetieth of the last century a new initiative aiming at early identification of patients with familial hypercholesterolaemia (FH) endangered by myocardial infarction and premature death emerged in Utah, USA. Its goal comprised diagnosis of the disease in asymptomatic stadium focusing on relatives of patients with a history of an ischaemic event and prevention of premature death and prevention of premature death and vascular events by early initiation of lipid lowering medications.